STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal

AI Summary

A gene-editing startup in the United States has launched with $230 million in funding and secured a licensing deal with a Chinese company. The company also executed a reverse merger with an existing biotech firm, signaling strong momentum in the gene-editing sector.

A new gene-editing startup negotiated contracts with a Chinese company, raised $230 million in funding, and executed a reverse-merger with a preexisting biotech company.